ConductScience.org, home

Paper32550266

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.

Dowsett M and 18 others. NPJ Breast Cancer, 2020. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. Papers, record 32550266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32550266

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
PubMed
Journal
NPJ Breast Cancer
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
1.96
iCite
Revised in PubMed
2025-05-30
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dowsett MMitch
2Ellis MJMatthew Jhttps://orcid.org/0000-0002-8467-8534
3Dixon JMJ Michael
4Gluz OOleg
5Robertson JJohn
6Kates RRonald
7Suman VJVera J
8Turnbull AKArran K
9Nitz UUlrike
10Christgen MMatthias
11Kreipe HHans
12Kuemmel SSherko
13Bliss JMJudith M
14Barry PPeter
15Johnston SRStephen R
16Jacobs SASamuel A
17Ma CXCynthia X
18Smith IEIan E
19Harbeck NNadiahttps://orcid.org/0000-0002-9744-7372

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
8671Cancer Research UKUnited KingdomPubMedPubMed
U01 CA114722NCI NIH HHSUnited StatesU01CA114722PubMedNIH RePORTER
U10 CA076001NCI NIH HHSUnited StatesU10CA076001PubMedNIH RePORTER
25351Cancer Research UKUnited KingdomPubMedPubMed
U24 CA114736NCI NIH HHSUnited StatesU24CA114736PubMedNIH RePORTER
R01 CA095614NCI NIH HHSUnited StatesR01CA095614PubMedNIH RePORTER

Download CSV of grants

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128721378Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.NPJ Breast Cancer2016https://conductscience.org/library/papers/28721378PubMed
221555689
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
J Clin Oncol2011https://conductscience.org/library/papers/21555689PubMed
320716629Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.Ann Oncol2011https://conductscience.org/library/papers/20716629PubMed
421960707Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.J Natl Cancer Inst2011https://conductscience.org/library/papers/21960707PubMed
532550266Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.NPJ Breast Cancer2020https://conductscience.org/library/papers/32550266PubMed
632333293Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.Breast Cancer Res Treat2020https://conductscience.org/library/papers/32333293PubMed
712751376Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.Eur J Cancer2003https://conductscience.org/library/papers/12751376PubMed
81486427Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment.Br J Surg1992https://conductscience.org/library/papers/1486427PubMed
932368252Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.Ecancermedicalscience2020https://conductscience.org/library/papers/32368252PubMed
1021802721Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.Lancet2011https://conductscience.org/library/papers/21802721PubMed
1118083023Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.Eur J Cancer2008https://conductscience.org/library/papers/18083023PubMed
1230523750Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.J Clin Oncol2019https://conductscience.org/library/papers/30523750PubMed
1323958221
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Trials2013https://conductscience.org/library/papers/23958221PubMed
1428045625
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
J Clin Oncol2017https://conductscience.org/library/papers/28045625PubMed
1515767642Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.J Clin Oncol2005https://conductscience.org/library/papers/15767642PubMed
1617228000Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.J Natl Cancer Inst2007https://conductscience.org/library/papers/17228000PubMed
1722043057Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.J Natl Cancer Inst Monogr2011https://conductscience.org/library/papers/22043057PubMed
1817679728A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.J Clin Oncol2007https://conductscience.org/library/papers/17679728PubMed
1924203987An international Ki67 reproducibility study.J Natl Cancer Inst2013https://conductscience.org/library/papers/24203987PubMed

Download CSV of references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42315983Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer.Histopathology2026https://conductscience.org/library/papers/42315983PubMed
42211537The Neoadjuvant Approach to Treatment of Breast Cancer: Multidisciplinary Management to Improve Outcomes.Surg Oncol Insight2024https://conductscience.org/library/papers/42211537PubMed
42141291Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer.Eur Radiol2026https://conductscience.org/library/papers/42141291PubMed
41317270SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025).Clin Transl Oncol2026https://conductscience.org/library/papers/41317270PubMed
41021566Impact of COVID-19 on breast cancer patients and services in a UK region: Protocol for a mixed methods study.PLoS One2025https://conductscience.org/library/papers/41021566PubMed
40075655Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.Cancers (Basel)2025https://conductscience.org/library/papers/40075655PubMed
37567612Ki67 and breast cancer mortality in women with invasive breast cancer.JNCI Cancer Spectr2023https://conductscience.org/library/papers/37567612PubMed
37326826SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).Clin Transl Oncol2023https://conductscience.org/library/papers/37326826PubMed
37232817COVID-19 and Breast Cancer: Analysis of Surgical Management of a Large Referral Center during the 2020-2021 Pandemic Period.Curr Oncol2023https://conductscience.org/library/papers/37232817PubMed
37010651Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study.Breast Cancer Res Treat2023https://conductscience.org/library/papers/37010651PubMed
36897465Using Oncotype DX breast recurrence scoreĀ® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.Breast Cancer Res Treat2023https://conductscience.org/library/papers/36897465PubMed
36733464Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications.Breast Cancer (Dove Med Press)2023https://conductscience.org/library/papers/36733464PubMed
36506043Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/36506043PubMed
36334188Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.Breast Cancer Res Treat2023https://conductscience.org/library/papers/36334188PubMed
36299379Tailored treatment strategies for cancer patients during COVID-19 pandemic.Rep Pract Oncol Radiother2022https://conductscience.org/library/papers/36299379PubMed
36262803
Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors.
Contemp Clin Trials Commun2022https://conductscience.org/library/papers/36262803PubMed
35992886Research trends and hotspots of breast cancer management during the COVID-19 pandemic: A bibliometric analysis.Front Oncol2022https://conductscience.org/library/papers/35992886PubMed
34979596Impact of the COVID-19 Pandemic on the Diagnosis and Surgery of Breast Cancer: A Multi-Institutional Study.J Breast Cancer2021https://conductscience.org/library/papers/34979596PubMed
34965950Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.Clin Cancer Res2022https://conductscience.org/library/papers/34965950PubMed
34779146TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.Cancer Med2021https://conductscience.org/library/papers/34779146PubMed

See all 30 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32550266

GET https://conductscience.org/api/papers/v1/32550266/cited_by?page=2